Eli lilan company has launched Zep bound a newly introduced treatment option featuring tepati in single does files targeted for distribution through Lily Direct's self-pay Channel Zep bound is priced over 50% lower than other incret in medications this strategic move aims to enhance accessibility and affordability in Diabetes Care potentially reshaping the market landscape and offering cost-effective choices for patients and investors alike